Literature DB >> 8424732

Randomized clinical trials on medical treatment of glaucoma. Are they appropriate to guide clinical practice?

L Rossetti1, I Marchetti, N Orzalesi, N Scorpiglione, V Torri, A Liberati.   

Abstract

A systematic quantitative and qualitative overview of published randomized clinical trials was undertaken to assess the yield of medical treatment on the outcome of patients with primary open angle glaucoma. Reports of 102 randomized clinical trials were published between 1975 and 1991, totalling about 5000 patients. Only 16% (16/102) of the trials were, however, properly designed (ie, comparing an active treatment with a placebo-treated or untreated control group) to answer the question of whether any medical treatment can effectively cure patients with primary open angle glaucoma. Pooled analysis showed a moderate yet statistically significant reduction in mean intraocular pressure (-4.9 mm Hg; 95% confidence interval [CI], -7.3 to -2.5 mm Hg); however, data on long-term visual field changes were available in only three randomized clinical trials, and their statistical combination failed to show a significant protective effect of active treatment (odds ratio, 0.75; 95% CI, 0.42 to 1.35). All of the remaining 86 randomized clinical trials looked at the effectiveness of one drug vs another in lowering intraocular pressure and were thus of no use in the overview. Practicing ophthalmologists should be aware that the effectiveness of pressure-lowering agents in the treatment of primary open angle glaucoma is still to be determined and that the vast majority of published trials are not appropriate to guide clinical practice. It is urgent to plan trials with end-point and follow-up duration that is fully relevant for the health of patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8424732     DOI: 10.1001/archopht.1993.01090010100034

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  17 in total

Review 1.  Non-penetrating glaucoma surgery: the state of play.

Authors:  J C Tan; R A Hitchings
Journal:  Br J Ophthalmol       Date:  2001-02       Impact factor: 4.638

2.  Treatment of raised intraocular pressure and prevention of glaucoma.

Authors:  R Wormald
Journal:  BMJ       Date:  2003-04-05

3.  [Medicinal glaucoma therapy. What can we learn from large randomized clinical trials?].

Authors:  A G M Jünemann; C Huchzermeyer; R Rejdak
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

4.  What's new in glaucoma treatment?

Authors: 
Journal:  Community Eye Health       Date:  2006-09

Review 5.  Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials.

Authors:  Philip C Maier; Jens Funk; Guido Schwarzer; Gerd Antes; Yngve T Falck-Ytter
Journal:  BMJ       Date:  2005-07-01

6.  Delaying treatment of ocular hypertension: the ocular hypertension treatment study.

Authors:  Michael A Kass; Mae O Gordon; Feng Gao; Dale K Heuer; Eve J Higginbotham; Chris A Johnson; John K Keltner; J Philip Miller; Richard K Parrish; M Roy Wilson
Journal:  Arch Ophthalmol       Date:  2010-03

Review 7.  Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.

Authors:  J A Balfour; M I Wilde
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 8.  Brinzolamide : a review of its use in the management of primary open-angle glaucoma and ocular hypertension.

Authors:  Risto S Cvetkovic; Caroline M Perry
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Drug reimbursement: indicators of inappropriate resource allocation.

Authors:  Bernard Bégaud; Ulf Bergman; Hans-Georg Eichler; Hubert G M Leufkens; Peter J Meier
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 10.  Current concepts in the pathophysiology of glaucoma.

Authors:  Renu Agarwal; Suresh K Gupta; Puneet Agarwal; Rohit Saxena; Shyam S Agrawal
Journal:  Indian J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.